Industry

Advancing Equitable Immunization Through Technology Transfer and Localized Needle-Free Injection Manufacturing GOLDEN, Colo. & CAIRO–(BUSINESS WIRE)–PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Memorandum of Understanding (MOU) agreement with the Egyptian Unified Procurement Authority (UPA) and EVA … [Read more…]

Strategic decision to restructure debt anchored in mission to provide high quality care, improve lives KENNETT SQUARE, Pa.–(BUSINESS WIRE)–Genesis HealthCare, Inc., along with its subsidiaries, announced today that it has taken steps to implement a financial restructuring to secure the long-term delivery of its mission. This process is designed to ensure that the Company can … [Read more…]

BEIJING–(BUSINESS WIRE)–#Antibody–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies. Prior to this licensing agreement, … [Read more…]

Ribbon-cutting Friday, July 11th – 11:00 a.m. Patient-centered model allows for utmost discretion and one-to-one HIV care TACOMA, Wash.–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF) is pleased to announce the dedication of its AHF Healthcare Center and Wellness Center in Tacoma, Washington, with a ribbon-cutting ceremony set for Friday, July 11. The state-of-the-art facility, AHF’s first in … [Read more…]

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus … [Read more…]

Special Meeting was validly adjourned until the appropriate court can make a final decision on the validity of the PIPE shares SAIF’s “announcement” about voting results demonstrates blatant disregard for the law and the Company’s bylaws and a repeated pattern of self-serving and unlawful actions by the Imposter Former Board Current Board remains the only … [Read more…]

No manual registration, pins, clamps or arrays AUSTIN, Texas–(BUSINESS WIRE)–VISIE Inc., the spatial computing company delivering the intelligence layer for surgical navigation and robotics, today announced a major technical milestone: the successful execution of all total knee arthroplasty (TKA) bone resections on cadaveric tissue, without the use of pins, clamps, arrays, or manual registration (Warning: … [Read more…]

ADHAND is a phase 3b placebo-controlled clinical trial evaluating the efficacy and safety of tralokinumab in adult patients living with moderate-to-severe atopic dermatitis on the hands who are candidates for systemic therapy.1 The 16-week interim results of the ADHAND trial met the primary and all key secondary endpoints, showing statistically significant results compared to placebo. … [Read more…]

First-of-its-kind heart pump implanted in Australia, based on a breakthrough wave membrane technology. Unlike existing devices, CorWave’s technology does not eliminate the effects of the native heartbeat and preserves the natural heart pulse. Early results suggest the pulsatility is preserved which could lead to a reduction of adverse events. The patient, suffering from advanced heart … [Read more…]

NEW YORK–(BUSINESS WIRE)–In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology. This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: … [Read more…]